0

Investor Presentation

January 20, 2017

Innovative Drug Delivery Solutions

1

2

To the extent any statements made in this presentation contain information that is not historical, these statements are

forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and

Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements

on our current expectations and projections about future events. Our actual results could differ materially from those

discussed in, or implied by, these forward-looking statements.

Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will,"

"may" and other similar expressions. In addition, any statements that refer to expectations, projections or other

characterizations of future events or circumstances are forward-looking statements. Forward-looking statements

include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and

Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new

pharmaceutical products, the impact of competitive products and pricing, new product development and launch,

reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax

rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from

time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities

Commission. IntelGenx undertakes no obligation to update or revise any forward-looking statement.

2

Forward Looking Statements

2

2

3

• IntelGenx Corp. Founded• TSX-V (IGX)• OTCQX (IGXT)• Market Capitalization • Shares Issued• Shares Fully Diluted• Insider Ownership• Cash/Equivalent (As of Sept 30, 2016)

2003CAD$1.11

US$0.83CAD$71M

64.7M70.8M

15%US$5.7M

Analyst Coverage

Firm Analyst

H.C. Wainwright Swayampakula Ramakanth

Singular Research Greg Eisen

Company Snapshot

3

4

Advantages of Oral Thin Film Delivery

We are focused on areas where oral films

are particularly well-suited:

Develop and commercialize products that provide therapeutic advantages to patients

leveraging oral films, such as:

• Reduced side effects

• Improved bio-availability

• Response time versus existing drugs

• Lifecycle management

• Repurpose existing drugs for new indications using oral films

• “First-to-file” Generic drugs where high technology barriers to

entry exist in reproducing branded films

5

Clearly Defined BD StrategyBalancing Risks and Opportunities for an Optimized Portfolio

Overall

Risk

Time to MarketSlow Fast

Low

High

Drug Repurposing

Patient Benefits

Lifecycle Mgmt

FTF Generics

IntelGenx Future FocusDeal Value

Low

Medium

High

5

A Robust Product Pipeline to Address Significant Market Opportunities

6

6

7

• High dose version of Wellbutrin XL®

• Only approved, once-daily, bupropion HCl 450mg dose

in a single tablet

• Launched commercially October 2013 in partnership

with Edgemont Pharmaceuticals

• Sold US revenue to SWK Holdings for US$6M

• Development cost $2.5M, total revenue $15M = 6-fold

ROI

• Non-dilutive source of funding, will be used to advance

film projects

Successful Monetization of First In-House Development

7

8

• Licensing and development agreements entered for

four generic products

• IntelGenx granted Chemo exclusive worldwide license

to commercialize two generic tablets and U.S. license

for two other generic oral films

• IntelGenx to receive upfront, milestone, R&D

revenues and share of profits – total value of 7 digits

• Combined total market of four products is over $7B

• Chemo making a strategic move into novel drug

delivery products with IntelGenx as its partner

• Partnership could result in numerous future product

agreements

Strategic Partnership with Chemo Group

About Chemo Group:

• Founded in 1978

• 5,000 employees

• Head office in Spain

• Revenues of $1.2B annually

• Markets over 300 products

• Operating in over 40 countries

• 20 state-of-the-art facilities

• 9 specialized R&D centers

8

For Migraines

Leverages VersaFilm™ Technology

9

• European Mktg Approval – November 2015

• Co-development partnership with RedHill Biopharma

• Definitive agreement signed July 2016 with

Grupo Juste for Spain & additional territories

• Definitive agreement signed Dec 2016 with

Pharmatronic for South Korea

• Actively pursuing several opportunities to open new

markets - negotiations with future commercialization

partners ongoing

• Planned USA submission to FDA Q1/2017

• Expected USA launch Q3/2017

9

For Erectile Dysfunction

• Accelerates our partnering of this product

for commercializing Tadalafil in the U.S.

• Containing tadalafil (Cialis® - Eli Lilly),

a leading molecule in the ED market

• Demonstrated bioequivalence to Cialis®

• Orally disintegrating films without need

for water provide unprecedented patient

convenience and a discrete dosing

alternative

• 505(b)(2) USA NDA submission in

Q2/2017

• Expected USA launch Q2/2018

10

IntelGenx secured license from Lilly for

Tadalfil ED dosing patent ‘166

10

For Schizophrenia & Bipolar 1 Disorder

11

• The first oral thin film using IntelGenx

proprietary drug delivery technology,

VersaFilm™, for treatment of

schizophrenia & bipolar 1 disorder

• Fast-acting loxapine oral dosage – to

treat acute agitation and anxiety in non-

institutionalized patients with

schizophrenia & bipolar 1 disorder

• Reduces risk of pulmonary problems

and potential risk of violence and injury to

patients and others

• Formulation optimization stage – results

expected Q2 2017

11

For Mild Cognitive Impairment

12

• IntelGenx is repurposing Montelukast

for the treatment of MCI by leveraging

its VersaFilm™ technology

• The drug is known and approved for a

completely different indication (asthma)

Global Sales for AD by Patients Category (Global Data, 2013)

12

2

13

Clinical Data

0.0

100.0

200.0

300.0

400.0

500.0

600.0

0.00 5.00 10.00 15.00 20.00 25.00 30.00Monte

lukast

concentr

ation (

ng/m

L)

Time (hrs)

Montelukast Avg Plasma Profile

Test buccal film 10mg

Ref tablet 10mg

• Phase 1 clinical study in human successfully completed

• Significantly increased bioavailability after administration of VersaFilm compared to

commercial tablet

• Drug crosses blood/brain barrier when given as film

• Phase II-a study (proof of concept) to commence Q1/2017

• First efficacy data in humans available Q4/2017

• Several Pharma companies have expressed strong interest

Before

MMSE 13:

moderate to severe

dementia

MMSE 22:

mild dementia

After 2 Months of

Montelukast

13

14

Construction of Manufacturing Facility Completed

• 17,000 sq ft facility in Montreal -

construction completed in Q1 2016

• Facility to be fully operational by Q1 2017

• High capacity manufacturing and

packaging equipment

• Lower costs, controls quality

and de-risks investment

for new products

GROSS MARGINS of 40% PLUS

We have built a state-of-the-art

oral film development and manufacturing facility

14

Strengthened Management TeamOver 20 Employees, including 7 with Ph.D.’s

Andre Godin, CPA, CA

Executive VP, CFO

• 25+ years biotech/pharma

industry experience

• Member of the Canadian

Chartered Professional

Accountants and the

Canadian Institute of

Chartered Accountants

Nadine Paiement, M. Sc.

VP, Research & Development

• Co-inventor of IntelGenx

Trilayer Technology

• 15 years experience in

product development and

technology transfer

Edward Miller, B. Comm

Director, Investor Relations

• 15 years experience in

investor relations

• 10 + years experience in

pharmaceutical / biotech

Horst G. Zerbe, Ph. D.

Chairman, President & CEO

• Co-Founder of Listerine

breath strips

• 30+ years drug delivery /

pharma experience

• Holds over 40 patents in drug

delivery and numerous

scientific publications

15

Dana Matzen, Ph.D.

VP, Business & Corporate

Development

• 15 years experience in

pharmaceutical product

licensing

• Prev. Director, BD at Paladin

• Completed 13 transaction,

7 new product launches

John Durham, B. Sc.

VP, Operations

• 20+ years experience in

pharmaceutical

manufacturing, quality

management, product

development

• Held executive positions with

several Canadian and US

companies

15

16

The IntelGenx Advantage

1. History

• Dr. Zerbe a pioneer with over 30 plus years in oral films

2. Formulation Team

• Strong in applying biopharmaceutical aspects to formulation development

• Top quality scientists: highly creative, focused on problem solving & innovative approaches

• Experienced in developing films for oral (GI), sublingual & buccal absorption

3. Clearly Defined Corporate Strategy And Business Model

• Focus on drug repurposing, lifecycle management, patient benefits, and FTF

• Provider of comprehensive pharmaceutical services to industry partners

4. Competitive Manufacturing Capabilities

• First in Canada

• New state-of-the-art manufacturing facility

• Offer one-stop-shopping to our partners with lean operations keeping costs down

• Customized manufacturing equipment

16

Financial Results

17

17

Financial Performance

Revenue ($M)

3.33.6

5.1

1.7

0

1

2

3

4

5

6

First 9 mths 2016 First 9 mths 2015 2015 Full Year 2014 Full Year

Revenue

$M

18

18

Net Comprehensive Income & Adjusted EBITDA ($M)

-1.5

0.60.8

-2.2

-0.9

1.3

1.7

-1.6

-2.5

-2

-1.5

-1

-0.5

0

0.5

1

1.5

2

First 9 mths 2016 First 9 mths 2015 2015 Full Year 2014 Full Year

Net Income Adjusted EBITDA

$M

Financial Performance

19

19

Conclusion

20

20

21

Solid Platform for Growth

Significant Market Potential

• New manufacturing facility will offer many competitive advantages

• Strengthened management team to accelerate execution of business plan

• Implemented product sourcing strategy to identify high-value product opportunities

• Building strategic partnerships with relevant partners in the pharmaceutical industry

Solid Platform for Growth

21

22

Thank You!www.IntelGenx.com

Contact Info:Edward Miller, B.Comm.Director, Investor Relations+1-514-331-7440 ext. 217Edward@intelgenx.com

IntelGenx Corporate Offices6420 AbramsSaint-Laurent (Quebec)H4S 1Y2 Canadawww.intelgenx.com